EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis

W. Fokkens, M. Desrosiers, R. Harvey, C. Hopkins, J. Mullol, C. Philpott, I. Alobid, W. T. Anselmo-Lima, C. Bachert, F. Baroody, M. Bernal-Sprekelsen, C. von Buchwald, A. Cervin, N. Cohen, J. Constantinidis, L. De Gabory, R. Douglas, P. Gevaert, A. Hafner, P. HellingsG. Joos, L. Kalogjera, R. Kern, A. Knill, J. Kocks, B. N. Landis, J. Limpens, S. Lebeer, O. Lourenco, P. M. Matricardi, C. Meco, L. O Mahony, S. Reitsma, D. Ryan, R. Schlosser, B. Senior, Timothy Smith, T. Teeling, P. V. Tomazic, S. Toppila-Salmi, D. Y. Wang, D. Wang, L. Zhang, V. Lund

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence. METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence. RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility. CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.

Original languageEnglish (US)
Pages (from-to)162-168
Number of pages7
JournalRhinology
Volume57
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Guidelines
Social Media
Patient Participation
Evidence-Based Medicine
Practice Guidelines
Internet
Quality of Life
Research

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Fokkens, W., Desrosiers, M., Harvey, R., Hopkins, C., Mullol, J., Philpott, C., ... Lund, V. (2019). EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis. Rhinology, 57(3), 162-168. https://doi.org/10.4193/Rhin17.253

EPOS2020 : development strategy and goals for the latest European Position Paper on Rhinosinusitis. / Fokkens, W.; Desrosiers, M.; Harvey, R.; Hopkins, C.; Mullol, J.; Philpott, C.; Alobid, I.; Anselmo-Lima, W. T.; Bachert, C.; Baroody, F.; Bernal-Sprekelsen, M.; von Buchwald, C.; Cervin, A.; Cohen, N.; Constantinidis, J.; De Gabory, L.; Douglas, R.; Gevaert, P.; Hafner, A.; Hellings, P.; Joos, G.; Kalogjera, L.; Kern, R.; Knill, A.; Kocks, J.; Landis, B. N.; Limpens, J.; Lebeer, S.; Lourenco, O.; Matricardi, P. M.; Meco, C.; O Mahony, L.; Reitsma, S.; Ryan, D.; Schlosser, R.; Senior, B.; Smith, Timothy; Teeling, T.; Tomazic, P. V.; Toppila-Salmi, S.; Wang, D. Y.; Wang, D.; Zhang, L.; Lund, V.

In: Rhinology, Vol. 57, No. 3, 01.06.2019, p. 162-168.

Research output: Contribution to journalArticle

Fokkens, W, Desrosiers, M, Harvey, R, Hopkins, C, Mullol, J, Philpott, C, Alobid, I, Anselmo-Lima, WT, Bachert, C, Baroody, F, Bernal-Sprekelsen, M, von Buchwald, C, Cervin, A, Cohen, N, Constantinidis, J, De Gabory, L, Douglas, R, Gevaert, P, Hafner, A, Hellings, P, Joos, G, Kalogjera, L, Kern, R, Knill, A, Kocks, J, Landis, BN, Limpens, J, Lebeer, S, Lourenco, O, Matricardi, PM, Meco, C, O Mahony, L, Reitsma, S, Ryan, D, Schlosser, R, Senior, B, Smith, T, Teeling, T, Tomazic, PV, Toppila-Salmi, S, Wang, DY, Wang, D, Zhang, L & Lund, V 2019, 'EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis', Rhinology, vol. 57, no. 3, pp. 162-168. https://doi.org/10.4193/Rhin17.253
Fokkens W, Desrosiers M, Harvey R, Hopkins C, Mullol J, Philpott C et al. EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis. Rhinology. 2019 Jun 1;57(3):162-168. https://doi.org/10.4193/Rhin17.253
Fokkens, W. ; Desrosiers, M. ; Harvey, R. ; Hopkins, C. ; Mullol, J. ; Philpott, C. ; Alobid, I. ; Anselmo-Lima, W. T. ; Bachert, C. ; Baroody, F. ; Bernal-Sprekelsen, M. ; von Buchwald, C. ; Cervin, A. ; Cohen, N. ; Constantinidis, J. ; De Gabory, L. ; Douglas, R. ; Gevaert, P. ; Hafner, A. ; Hellings, P. ; Joos, G. ; Kalogjera, L. ; Kern, R. ; Knill, A. ; Kocks, J. ; Landis, B. N. ; Limpens, J. ; Lebeer, S. ; Lourenco, O. ; Matricardi, P. M. ; Meco, C. ; O Mahony, L. ; Reitsma, S. ; Ryan, D. ; Schlosser, R. ; Senior, B. ; Smith, Timothy ; Teeling, T. ; Tomazic, P. V. ; Toppila-Salmi, S. ; Wang, D. Y. ; Wang, D. ; Zhang, L. ; Lund, V. / EPOS2020 : development strategy and goals for the latest European Position Paper on Rhinosinusitis. In: Rhinology. 2019 ; Vol. 57, No. 3. pp. 162-168.
@article{51f768086d6649c989b5c8e599f0174f,
title = "EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis",
abstract = "BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence. METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence. RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility. CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.",
author = "W. Fokkens and M. Desrosiers and R. Harvey and C. Hopkins and J. Mullol and C. Philpott and I. Alobid and Anselmo-Lima, {W. T.} and C. Bachert and F. Baroody and M. Bernal-Sprekelsen and {von Buchwald}, C. and A. Cervin and N. Cohen and J. Constantinidis and {De Gabory}, L. and R. Douglas and P. Gevaert and A. Hafner and P. Hellings and G. Joos and L. Kalogjera and R. Kern and A. Knill and J. Kocks and Landis, {B. N.} and J. Limpens and S. Lebeer and O. Lourenco and Matricardi, {P. M.} and C. Meco and {O Mahony}, L. and S. Reitsma and D. Ryan and R. Schlosser and B. Senior and Timothy Smith and T. Teeling and Tomazic, {P. V.} and S. Toppila-Salmi and Wang, {D. Y.} and D. Wang and L. Zhang and V. Lund",
year = "2019",
month = "6",
day = "1",
doi = "10.4193/Rhin17.253",
language = "English (US)",
volume = "57",
pages = "162--168",
journal = "Rhinology",
issn = "0300-0729",
publisher = "University Hospital Utrecht",
number = "3",

}

TY - JOUR

T1 - EPOS2020

T2 - development strategy and goals for the latest European Position Paper on Rhinosinusitis

AU - Fokkens, W.

AU - Desrosiers, M.

AU - Harvey, R.

AU - Hopkins, C.

AU - Mullol, J.

AU - Philpott, C.

AU - Alobid, I.

AU - Anselmo-Lima, W. T.

AU - Bachert, C.

AU - Baroody, F.

AU - Bernal-Sprekelsen, M.

AU - von Buchwald, C.

AU - Cervin, A.

AU - Cohen, N.

AU - Constantinidis, J.

AU - De Gabory, L.

AU - Douglas, R.

AU - Gevaert, P.

AU - Hafner, A.

AU - Hellings, P.

AU - Joos, G.

AU - Kalogjera, L.

AU - Kern, R.

AU - Knill, A.

AU - Kocks, J.

AU - Landis, B. N.

AU - Limpens, J.

AU - Lebeer, S.

AU - Lourenco, O.

AU - Matricardi, P. M.

AU - Meco, C.

AU - O Mahony, L.

AU - Reitsma, S.

AU - Ryan, D.

AU - Schlosser, R.

AU - Senior, B.

AU - Smith, Timothy

AU - Teeling, T.

AU - Tomazic, P. V.

AU - Toppila-Salmi, S.

AU - Wang, D. Y.

AU - Wang, D.

AU - Zhang, L.

AU - Lund, V.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence. METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence. RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility. CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.

AB - BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence. METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence. RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility. CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.

UR - http://www.scopus.com/inward/record.url?scp=85067292511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067292511&partnerID=8YFLogxK

U2 - 10.4193/Rhin17.253

DO - 10.4193/Rhin17.253

M3 - Article

C2 - 30810118

AN - SCOPUS:85067292511

VL - 57

SP - 162

EP - 168

JO - Rhinology

JF - Rhinology

SN - 0300-0729

IS - 3

ER -